Gossamer Bio FY2024 EPS Estimate Raised by Leerink Partnrs

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities research analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Gossamer Bio in a report released on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($0.32) per share for the year, up from their prior forecast of ($0.41). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. Leerink Partnrs also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.95) EPS and FY2026 earnings at ($0.79) EPS.

GOSS has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a report on Monday, November 11th. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Gossamer Bio presently has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Down 3.9 %

Gossamer Bio stock opened at $0.74 on Thursday. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.60. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a market capitalization of $167.71 million, a price-to-earnings ratio of -2.31 and a beta of 1.96. The firm has a 50-day moving average price of $0.93 and a two-hundred day moving average price of $0.86.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million.

Institutional Trading of Gossamer Bio

Institutional investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. increased its stake in shares of Gossamer Bio by 30.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock valued at $1,862,000 after acquiring an additional 442,895 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after purchasing an additional 74,920 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio in the 3rd quarter worth $67,000. US Bancorp DE bought a new stake in shares of Gossamer Bio in the 3rd quarter worth $39,000. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Gossamer Bio by 26.7% in the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after buying an additional 25,000 shares during the period. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.